Translational Development Acquisition CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
Translational Development Acquisition Corp. reports net income of $1.33M for Q1 2026, driven by investment income, while continuing its search for a business combination before its June 2026 deadline.
NASDAQ
Translational Development Acquisition Corp. reports increased trust account value and net income, but faces a going concern warning as its business combination deadline approaches.
NASDAQ
Translational Development Acquisition Corp. reported a net income of $1.62 million for Q2 2025, driven by dividends from its Trust Account, but faces going concern doubts due to its limited operating cash and upcoming business combination deadline.
NASDAQ
Translational Development Acquisition Corp. reports a net income of $1.48 million for the quarter ended March 31, 2025, driven by dividends earned on marketable securities.